Development of a plant-grown subunit vaccine against respiratory syncytial virus

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$581,068.00
Award Year:
2010
Program:
SBIR
Phase:
Phase I
Contract:
1R43AI082834-01A1
Agency Tracking Number:
AI082834
Solicitation Year:
2010
Solicitation Topic Code:
NIAID
Solicitation Number:
PHS2010-2
Small Business Information
VIROGENOMICS, INC.
VIROGENOMICS, INC., 9020 SW WASHINGTON SQUARE RD, TIGARD, OR, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
045283590
Principal Investigator
 RENEE SHIRLEY
 (503) 626-1144
 RSHIRLEY@VIROGENOMICS.COM
Business Contact
Phone: (503) 626-1144
Email: gil.miller@virogenomics.com
Research Institution
N/A
Abstract
DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV)-caused disease represents a significant health care burden worldwide. The RSV infects virtually all children throughout the world in both developed and developing countries. Re-infection is common because natural infection does not induce lasting immunity. Also, severe RSV infections are increasingly occurring among the elderly. In spite of wide-scale efforts to produce an effective vaccine against RSV, no vaccine is yet available. Development of an inexpensive edible plant-based oral vaccine is an innovative approach for the control of RSV. The present study extends the strategy of using a plant-based oral vaccine to a respiratory pathogen for the first time. Even if lasting immunity is not obtained with the plant-based vaccine, it would be relatively low in cost to use such a vaccine during successive RSV seasons. We have shown previously that oral immunization of mice with transgenic tomato fruit expressing an RSV- subunit protein, i.e., the F-protein, induces a systemic immune response. This proof of principle Phase I study will optimize the expression of the RSV-F protein in the transgenic tomato fruit and determine the capacity of this orally-given antigenic protein to protect against an RSV challenge in two commonly-used models for RSV studies, the Balb/c mouse and the cotton rat. Success will validate the further development of our tomato- based vaccine against RSV and set the stage for a Phase II study. Such a vaccine will definitely make a difference and have an enduring impact on human health. PUBLIC HEALTH RELEVANCE: Respiratory syncytial virus-caused disease is a significant health care burden worldwide, but no vaccine is available. We are developing an inexpensive vaccine using tomato plants to control this virus.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government